Valuation: Sensorion

Market Cap 13Cr 15Cr 12Cr 11Cr 21Cr 1.41TCr 22Cr 144.45Cr 56Cr 693.53Cr 56Cr 55Cr 2.41TCr P/E 2026 *
-16.9x
P/E 2027 * -3.9x
Enterprise Value -15.19L -17.3L -13.98L -13.02L -24.56L -16Cr -25.06L -1.68Cr -65.14L -8.07Cr -64.94L -63.54L -28Cr EV / Sales 2026 *
-0.07x
EV / Sales 2027 * 20.4x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week+7.89%
Current month+6.98%
1 month-40.19%
3 months-39.47%
6 months-24.48%
Current year-24.93%
1 week 0.22
Extreme 0.222
0.26
1 month 0.22
Extreme 0.222
0.42
Current year 0.22
Extreme 0.222
0.81
1 year 0.22
Extreme 0.222
0.81
3 years 0.15
Extreme 0.1544
1.04
5 years 0.15
Extreme 0.1544
2.29
10 years 0.15
Extreme 0.1544
7.74
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Date Insider Type Main position Quantity % Market Cap.
06/02
Redmile Biopharma Investments III LP
BuyCompany 1,89,28,571 6.2956%
31/01
Sofinnova Partners SAS
BuyCompany 1,07,14,285 3.5636%
18/24/18
Redmile Biopharma Investments III LP
BuyCompany 27,81,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+7.89%-11.23%-17.99% 15Cr
+0.21%+4.62%+0.57%+6.16% 4.86TCr
+0.12%+10.45%+408.29%+600.97% 3.99TCr
+5.17%+9.47%+24.96%-9.60% 3.39TCr
+2.02%+4.91%+18.59%+63.06% 3.23TCr
+0.69%+1.04%+14.23%+30.86% 2.47TCr
+0.40%+12.51% - - 1.66TCr
+2.64%+6.00%+69.30%+126.33% 1.55TCr
+0.09%+0.35%+12.96%+17.65% 1.36TCr
+0.77%+10.67%+17.58%-30.04% 1.34TCr
Average +1.18%+6.86%+61.70%+87.49% 2.39TCr
Weighted average by Cap. +1.38%+7.14%+88.18%+128.41%

Financials

2026 *2027 *
Net sales 2.19Cr 2.49Cr 2.01Cr 1.87Cr 3.54Cr 236.69Cr 3.61Cr 24Cr 9.38Cr 116.18Cr 9.35Cr 9.15Cr 404.33Cr 63.95L 72.84L 58.86L 54.85L 1.03Cr 69Cr 1.06Cr 7.08Cr 2.74Cr 34Cr 2.73Cr 2.68Cr 118.3Cr
Net income -43.4L -49.43L -39.95L -37.22L -70.2L -47Cr -71.63L -4.8Cr -1.86Cr -23Cr -1.86Cr -1.82Cr -80Cr -5.06Cr -5.77Cr -4.66Cr -4.34Cr -8.19Cr -548.35Cr -8.36Cr -56Cr -22Cr -269.16Cr -22Cr -21Cr -936.75Cr
Net Debt -13Cr -15Cr -12Cr -11Cr -21Cr -1.43TCr -22Cr -146.14Cr -57Cr -701.6Cr -56Cr -55Cr -2.44TCr -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
02/26/02 0.2530 -0.20% 3,80,854
01/26/01 €0.2535 +7.19% 10,16,255
30/26/30 €0.2365 +1.94% 7,98,938
29/26/29 €0.2320 -1.07% 4,94,785
26/26/26 €0.2345 0.00% 9,19,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2535EUR
Average target price
1.212EUR
Spread / Average Target
+378.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock